1. Indications and Usage
\nHR+\/HER2- Advanced or Metastatic Breast Cancer:
\nIndicated for the treatment of pre\/perimenopausal and postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.
\nCombination Therapy:
\nIn combination with an aromatase inhibitor as initial endocrine-based therapy.
\nIn combination with fulvestrant in patients with disease progression following endocrine therapy.
\n2. Dosage and Administration
\nRecommended Dosage:
\nDose: 600 mg (three 200 mg tablets) orally once daily.
\nCycle: Continue for 21 consecutive days, followed by a 7-day rest period (28-day cycle).
\nAdministration: Administer with or without food at approximately the same time each day (preferably in the morning). Swallow tablets whole; do not crush, split, or chew.
\nMonitoring:
\nPerform complete blood counts (CBC) and liver function tests (LFTs) prior to starting treatment and monitor periodically. Obtain an ECG prior to initiation.
\n3. Mechanism of Action
\nCDK4\/6 Inhibition:
\nRibociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4\/6).
\nCell Cycle Arrest:
\nCDK4\/6 bind to cyclin D1 to phosphorylate the retinoblastoma protein (Rb), leading to cell cycle progression. Ribociclib inhibits this phosphorylation, resulting in G1 phase cell cycle arrest and suppression of tumor cell proliferation.
\n4. Safety and Warnings
\nQTc Prolongation:
\nRibociclib can prolong the QT interval. It is contraindicated in patients with congenital long QT syndrome. ECG monitoring is required.
\nSevere Neutropenia:
\nSevere neutropenia (Grade 3 or 4) is a common adverse reaction. Monitor CBC regularly.
\nHepatobiliary Toxicity:
\nIncreases in transaminases (AST\/ALT) have been observed. Monitor LFTs regularly.
\nPulmonary Toxicity:
\nInterstitial lung disease (ILD)\/pneumonitis has been reported. Monitor for pulmonary symptoms.
\n5. Adverse Reactions
\nMost Common:
\nNausea, fatigue\/asthenia, diarrhea, headache, insomnia, vomiting, abdominal pain, and pyrexia.
\nLaboratory Abnormalities:
\nNeutropenia, leukopenia, lymphopenia, anemia, increased AST\/ALT, increased creatinine.
\n6. Drug Interactions
\nStrong CYP3A Inhibitors:
\nAvoid concomitant use with strong CYP3A inhibitors (e.g., itraconazole, clarithromycin, ritonavir) as they significantly increase Ribociclib plasma concentrations.
\nCYP Substrates:
\nMay increase exposure to CYP2D6 and P-gp substrates.
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Ribociclib Succinate.
\nStorage:
\nStore at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F). Keep in the original package to protect from moisture.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name:\u00a0 \u51ef\u4e3d\u9686\u00ae\uff08Kisqali\u00ae\uff09
\nGeneric Name: Ribociclib Succinate
\nStrength: 200 mg per tablet, 63 film-coated tablets per box
\nManufacturer: Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd. \/ Novartis Pharmaceutical Manufacturing LLC
\nMarketing Authorization Holder: Novartis Pharma AG, domestic entrusted holder: Beijing Novartis Pharmaceutical Co., Ltd.
\nApproval Date in China: January 19, 2023
\nRegistration Number: \u56fd\u836f\u51c6\u5b57HJ20230003
\nStorage: Store in original packaging at 20\u2103 ~ 25\u2103, temperature fluctuation between 15\u2103 ~ 30\u2103 is allowed, protect from light, keep out of reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Ribociclib Succinate \uff08Kisqali\uff09<\/p>\n","protected":false},"featured_media":3360,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[80],"product_cat":[27],"product_tag":[],"class_list":["post-3359","product","type-product","status-publish","has-post-thumbnail","product_brand-novartis","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n